Melleva

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Melleva

What is Melleva? (Overview and Quick Facts)

Property Description
Active Ingredients Ethinyl Estradiol (Estrogen), Levonorgestrel (Progestin)
Form Oral Tablet
Pharmacological Class Combined Oral Contraceptive (COC), Hormonal Contraceptive
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic Steroid Hormones

What Type of Medication is Melleva?

Melleva is formally classified as a Combined Oral Contraceptive (COC), belonging to the broad pharmacological class of Hormonal Contraceptives. This preparation is consistently delivered to the patient as an oral tablet and its primary therapeutic purpose is to achieve contraception, effectively preventing pregnancy. The designation as a COC distinguishes it from single-hormone contraceptives, such as progestin-only pills, by utilizing two distinct active ingredients to provide comprehensive hormonal regulation. This combination ensures a method for the management of fertility in the adult female population.

Melleva's Composition: Synthetic Estrogen and Progestin

The core identity of Melleva is defined by its two principal active ingredients: the synthetic estrogen, Ethinyl Estradiol (EE), and the synthetic progestin, Levonorgestrel (LNG). Both are categorized as synthetic steroid hormones, chemically derived to mimic the functions of the body’s natural estrogen and progesterone, respectively. This combination is recognized for its use in hormonal birth control. As a combination product, Melleva integrates these two agents within a single tablet, utilizing standard solid oral excipients for its structure. The specific formulation of ethinyl estradiol and levonorgestrel is one of the most common and established hormonal compositions available globally.

How Does Melleva Generally Achieve Contraception?

Melleva achieves its general purpose of preventing conception through systemic hormonal suppression of the female reproductive system. The medication introduces hormone levels that primarily inhibit the signals from the brain necessary to trigger the release of an egg, a process known as the inhibition of ovulation. This primary action is reinforced by the progestin component, which thickens the cervical mucus to impede sperm movement and alters the lining of the uterus (endometrium) to discourage the establishment of a fertilized egg. This multi-layered defense mechanism provides the effectiveness required for the prevention of pregnancy in a typical use scenario.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Melleva?

The official safety profile of Melleva (Ethinyl Estradiol/Levonorgestrel) is defined by categories of observed adverse reactions, potential serious risks, and specific restrictions on use, as documented in regulatory labeling.

Adverse Reactions by Frequency and System

Side effects are classified by how often they occur. Very common reactions, reported in ge 10% of users, typically involve headache/migraine, breast pain/tenderness, and breakthrough bleeding or spotting (irregular uterine bleeding). Common effects (ge 1% to < 10%) frequently include nausea, vomiting, abdominal pain, weight increase, and mood changes, including depression. These effects are often more pronounced during the initial cycles of treatment.

Serious Adverse Reactions

The most critical safety concerns listed in regulatory documents involve the vascular system. Use is associated with a rare but serious risk of Venous Thromboembolism (VTE) (including deep vein thrombosis and pulmonary embolism) and Arterial Thromboembolism (ATE) (including stroke and myocardial infarction). This risk is highest during the first year of use. Additionally, the label documents the potential for hepatic neoplasms (liver tumors) and may increase the risk of certain cancers with long-term use.

Safety-Related Restrictions

Regulatory labeling specifies strict constraints (contraindications) for use. Melleva is prohibited in women over 35 who smoke, those with a history of VTE or ATE, individuals with uncontrolled hypertension, or those with known hormone-sensitive malignancies (e.g., breast cancer). Use is also restricted in cases of severe liver disease. The product label explicitly states that Melleva does not protect against HIV infection or other sexually transmitted diseases.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for an overdose of combined oral contraceptives like Melleva, which contains Ethinyl Estradiol and Levonorgestrel, classifies the event as not likely to be life-threatening in an acute setting. However, immediate medical attention must be sought upon suspicion of an overdosage amount.

The documented clinical manifestations are primarily related to the high level of sex hormones. These commonly include nausea and vomiting. A key physiological sign for female patients is withdrawal bleeding, which may present as heavy vaginal bleeding and can be delayed by several days.

Mandatory Emergency Actions and Supportive Care

Action Required Management Statement (Regulatory-Aligned)
Urgent Contact Seek immediate medical attention or contact emergency services/Poison Control for expert guidance.
Antidote No specific antidote is known for the active ingredients in Melleva.
Treatment Management is restricted to symptomatic and supportive treatment. This may involve medical supervision, monitoring of vital signs, and, in severe or extreme cases, officially described procedures such as the administration of activated charcoal.

This regulatory information dictates the required response: while the acute toxic risk is low, prompt professional guidance is necessary to manage documented symptoms and ensure stable recovery under supportive care protocols.

Therapeutic Uses of Melleva

What Melleva Treats: Main Uses and Benefits

The combined oral contraceptive Melleva is commonly used for planned fertility management and is relevant across therapeutic domains where additional symptomatic support is needed to help manage hormonally-related symptoms. In addition to preventing pregnancy, combined oral contraceptives are also sometimes used to treat heavy or irregular menstruation and endometriosis.


Key Therapeutic Support Areas

Melleva provides support for planned control over the reproductive cycle and contributes to easing the overall symptom load associated with specific conditions. The medication is commonly used across conditions presenting with disruptive symptom manifestations, which may involve symptoms related to heavy menstrual bleeding (menorrhagia), menstrual cramping (primary dysmenorrhea), and moderate acne vulgaris. The therapeutic support may assist with maintaining functional stability during symptomatic periods.

“It is commonly used to help with establishing a more predictable cycle and easing discomfort that may interfere with daily functioning.”

Melleva is applied in clinical settings that involve recurrent or episodic manifestations. It is used for managing symptom clusters that may create noticeable functional strain, such as cyclical pain and flow irregularities, and provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Cyclical Discomfort
Melleva may assist with maintaining functional stability during periods of heightened symptoms associated with primary dysmenorrhea and is used for managing symptoms related to menstrual bleeding disorders.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Melleva is officially indicated for use by females of reproductive potential to prevent pregnancy, specifically after menarche. Use is not indicated for postmenopausal women or for females before menarche.

Use is formally contraindicated in several population groups, primarily due to an increased risk of serious cardiovascular events. These absolute contraindications include women over age 35 who smoke, those with a history of or high risk for arterial or venous blood clots (thrombotic diseases), or those with uncontrolled hypertension. The medication must also not be used if the patient has certain conditions such as thrombogenic heart valve disease, severe cirrhosis, liver tumors, or known or suspected breast cancer.

Melleva is also contraindicated during a known or suspected pregnancy. For women who are breastfeeding (lactating), use is not recommended according to regulatory labeling. Additional restrictions require that the medication be temporarily stopped at least four weeks before and through two weeks after any major surgery or prolonged immobilization.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Melleva's effectiveness can be reduced by co-administration with other medicines that affect the way it is processed by the body. This is primarily due to pharmacokinetic interactions, where certain drugs accelerate the metabolism of Melleva's active progestogen component.

Key Interacting Medicinal Product Categories

The most significant interactions involve medicines that are hepatic enzyme inducers, specifically those that induce the Cytochrome P450 (CYP) enzyme system, such as CYP3A4. The accelerated breakdown of Melleva leads to lower plasma concentrations and a loss of its contraceptive action.

  • Anticonvulsants/Anti-epileptics (e.g., carbamazepine, phenytoin, phenobarbital, primidone, oxcarbazepine)
  • Antibacterials (e.g., rifampicin, rifabutin)
  • Antivirals (e.g., ritonavir, efavirenz, nevirapine)
  • Antifungals (e.g., griseofulvin)
  • Herbal Products (e.g., St. John's wort (Hypericum perforatum))

These combinations are classified as clinically significant interactions that necessitate caution. When Melleva is co-administered with any of these enzyme-inducing products, or during the subsequent 28 days after stopping the inducing drug, there is a risk of contraceptive failure. In such cases, official regulatory guidance indicates that a reliable non-hormonal method of contraception should be used.

Mechanism of Action

Modulation of the Hypothalamic-Pituitary-Ovarian (HPO) Axis

Melleva acts via its synthetic hormones to engage Progesterone and Estrogen receptors in the brain, primarily in the hypothalamus and pituitary gland. This receptor binding generates a negative feedback signal, resulting in the suppression of the cyclic surge of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), which results in the inhibition of ovulation.


Alteration of Cervical and Uterine Physiology

The drug's active ingredients, particularly the progestin component, act locally on peripheral tissues to modulate the reproductive tract environment. This action modifies the consistency of cervical mucus, causing it to thicken substantially. It also influences the endometrium (uterine lining) to modulate the uterine environment. These mechanisms create physical and environmental barriers that interfere with sperm migration and affect implantation.

Dosage and Administration Information

Instruction Map: How to use Melleva — Official Administration Guidelines

The usage of Melleva (Levonorgestrel and Ethinyl Estradiol) is strictly defined by structured administration patterns. The medication is administered via the oral route as a tablet. The standard active tablet contains the fixed dose of 0.15 mg of Levonorgestrel and 0.03 mg of Ethinyl Estradiol.


Administration Scope

The regimen requires taking one active tablet once daily according to a cyclic pattern, most commonly involving 21 active tablets followed by 7 inactive or placebo tablets. The critical procedural condition is that the tablet must be taken at the same time every day to maintain consistent hormone levels, independent of meals.

Specific dosing start protocols are defined, such as the Day 1 Start (first day of menses) or the Sunday Start. If initiation occurs later than the first day of the cycle, it is necessary to use a non-hormonal backup contraceptive method for the first seven days of active tablet intake.

Procedural Rules and Duration

Usage is intended for long-term, continuous cyclic use, with cycles typically lasting 28 or 91 days. Dosing for postmenarchal females is the same as the adult regimen. However, non-lactating individuals are advised to delay initiation until four weeks after delivery. Detailed protocols are also documented for handling a missed dose within the cycle, which may necessitate specific actions to be taken depending on the timing of the missed tablet.

Recent Clinical Evidence

Research evidence / Overview of Studies for Melleva

Evidence for Use in Contraception (Prevention of Pregnancy)

The research base for Melleva's primary purpose—the prevention of pregnancy—is substantial. Studies primarily used were large-scale Phase 3 Randomized Controlled Trials (RCTs) and subsequent long-term observational studies that tracked healthy females of reproductive potential. Research examined outcomes related to systemic or functional imbalance, specifically monitoring the inhibition of ovulation and its effects on the reproductive cycle. The key outcome measured was the rate of unintended pregnancies (reported via the Pearl Index method), alongside observing the effects on general cycle regularity.

Studies described patterns showing a consistently observed pattern related to pregnancy rates when the product was used according to the schedule. Studies monitored patterns related to suppression of ovarian activity across the observed time intervals. Evidence is limited concerning long-term outcomes after many years of continuous use, as this information is often derived from epidemiological surveillance rather than extended, controlled clinical trials.


Evidence for Management of Menstrual Symptoms and Disorders

Melleva was studied for conditions characterized by fluctuating or episodic manifestations, including those involving outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. Research has explored its use in conditions presenting with cycles of stability and flare-ups, such as heavy bleeding and menstrual pain.

Studies on Heavy Menstrual Bleeding

Research relies on controlled clinical trials and systematic reviews. Key study outcomes examined included the objective quantification of menstrual blood loss (MBL) volume and changes in cycle predictability. Studies reported observations of lower mean MBL volumes compared to initial measurements. Comparative evidence is lacking against a non-active control in some trials.

Studies on Primary Dysmenorrhea

Evidence comes from systematic reviews of RCTs. Studies monitored outcomes related to physical discomfort, specifically changes in pain severity (using validated scales) and the tracking of supplementary pain medication usage. Findings describe patterns observed in the studies that using the combined oral contraceptive was associated with reported lower pain scores and changes in the usage of supplementary pain relievers.


Evidence Gaps and Areas of Uncertainty

Results apply only to the populations studied, and data for certain groups remain insufficient. Clinical studies often excluded women with certain comorbidities or women over a certain age who smoke, meaning limited information is available for these specific subgroups. Subgroup findings are uncertain for populations such as very young adolescents or women with high BMI. Research provides context but not individual predictions.

Key Studies & References

  1. Ethinyl Estradiol and Levonorgestrel (Oral Contraceptive)
  2. General overview of uses for combination birth control pills

Frequently Asked Questions (FAQ)

Common questions about Melleva (FAQ)


Q: How quickly does Melleva typically start working?

Official product information indicates that the body requires time to adjust to the medication before pregnancy is prevented. Regulatory documents state that to achieve contraceptive protection, a non-hormonal backup method (such as condoms) is generally advised during the first seven days when treatment is started.


Q: How long do the general effects of Melleva last?

The contraceptive effect of Melleva is dependent on maintaining consistent levels of synthetic hormones in the body. Regulatory documents state that taking the pill daily at the same time is necessary to maintain consistent hormone levels and sustain contraceptive effectiveness. If a dose is missed, the medication’s efficacy may be reduced.


Q: What should a patient generally know about taking Melleva long-term?

For individuals using Melleva long-term, official documents note that professional health monitoring may be required, especially concerning specific health parameters. Regulatory information warns that the risk of blood clots (VTE/ATE) is highest in the first year of use, and there is a documented potential risk of developing certain conditions, such as hepatic neoplasms (liver tumors), with extended use.


Q: Why do some people experience [non-specific side effect, e.g., mild nausea] when starting Melleva?

Regulatory guidance notes that common side effects, such as nausea and vomiting, are often more noticeable during the initial cycles of treatment. This is typically related to the body adjusting to the new, consistent levels of the synthetic hormones. This adjustment period often resolves as the body acclimates to the medication.


Q: What official information exists regarding Melleva and mental health conditions?

Official documentation lists mood changes, including depression, as a common documented side effect of Melleva. If severe depression or significant emotional distress occurs, contact a healthcare professional.


Q: How long did the clinical trials for Melleva last?

The clinical studies designed to demonstrate Melleva's effectiveness in preventing ovulation generally cover several menstrual cycles to ensure reliable data. Studies assessing the primary action of the medication, such as the inhibition of ovulation, often track outcomes over intervals like 84 days of continuous active use.


Q: How does Melleva affect a person's mood or energy levels?

Regulatory labels state that mood changes, including episodes of depression, are commonly documented side effects. Less frequently, official information also lists potential symptoms like fatigue and a feeling of weakness or lack of energy.


Q: Does Melleva have an effect on [common body system, e.g., blood pressure, sleep]?

Melleva is known to increase blood pressure in some individuals, and it is strictly contraindicated (should not be used) in women with uncontrolled high blood pressure. Additionally, the medication can cause fluid retention, which may sometimes affect other conditions, such as the frequency or severity of headaches.


Q: Is Melleva considered a controlled substance?

No. Official drug classification documents, such as the federal Controlled Substances Act, do not list Melleva (Levonorgestrel/Ethinyl Estradiol) as a controlled substance. It is regulated as a prescription hormonal contraceptive.


Q: Are there foods or drinks that commonly interfere with Melleva?

While the regulatory label primarily focuses on drug interactions, some evidence suggests that consuming large amounts of grapefruit juice may increase the levels of Melleva's active ingredients in the blood. Taking the pill with a meal may also help to reduce the feeling of initial nausea.


Q: Is it possible to take Melleva with common over-the-counter pain relievers?

Regulatory references suggest that taking Melleva with common pain relievers, such as acetaminophen, results in no significant additional risks when used at the usual recommended doses. The primary interactions listed in official documents are with certain prescription medicines that affect the liver.


Q: Does Melleva affect a person's ability to drive or operate machinery?

Official drug documentation does not typically include a specific warning against driving while taking Melleva. However, patients should be aware that documented side effects like dizziness and migraines may occur and could affect their ability to drive or use machinery safely.


Q: Is there a generic version of Melleva available?

Yes. Since Melleva contains a common and established hormonal composition (Levonorgestrel and Ethinyl Estradiol), official drug registries list multiple FDA-approved generic versions that contain the same active ingredients.


Q: Are there known interactions between Melleva and caffeine?

Regulatory references indicate that the estrogen component in Melleva (Ethinyl Estradiol) may affect how the body processes caffeine. This means it may increase the amount of caffeine present in the blood, potentially making a person more susceptible to caffeine-related side effects.


Q: How is Melleva generally eliminated from the body?

The active components of Melleva are processed extensively in the liver. According to the Clinical Pharmacology sections of the regulatory label, both the progestin and the estrogen components are primarily removed from the body via urine and feces.


Q: Can Melleva interact with alcohol?

Official documents state that alcohol does not directly interfere with the contraceptive action of Melleva. However, excessive alcohol consumption could potentially lead to vomiting, which might prevent the pill from being properly absorbed, or could impair memory, leading to a missed dose.


Q: Does Melleva require any specific monitoring (e.g., blood tests)?

While routine monitoring for all users is not universally required, official guidelines specify that women with certain pre-existing conditions, such as diabetes or prediabetes, may require monitoring of their glucose and lipid levels (fats in the blood) while using Melleva.


Q: Are there any known issues with abruptly stopping Melleva?

When Melleva use is discontinued, the body loses the continuous hormonal support, leading to withdrawal bleeding. The primary documented issue with stopping is the immediate loss of contraceptive protection, as ovulation will return, making pregnancy possible.


Q: Do regulatory agencies list any potential for abuse or dependence with Melleva?

Regulatory documents that assess the safety profile of the drug explicitly state that the potential for drug abuse or dependence with combination oral contraceptives is considered to be very low.


Q: What does the term 'contraindication' mean in the context of Melleva?

A contraindication is a critical term used in medicine to describe a specific condition or factor that serves as a reason to withhold a certain medical treatment due to the harm it would cause. In the context of Melleva, contraindications are conditions, such as a history of blood clots, that make the use of the pill unsafe.

How should Melleva be stored and disposed of?

How to Store and Dispose of Melleva?

The storage and disposal of Melleva (Ethinyl Estradiol and Levonorgestrel) must adhere strictly to official regulatory guidelines to maintain product stability and ensure household safety.

Storage Requirement Official Regulatory Rule
Temperature Range Store at controlled room temperature, between 20^circC and 25^circC (68^circF to 77^circF).
Protection Keep away from excess moisture, direct light, and heat. Do not freeze the tablets.
Packaging Keep the medicine in its original container or blister packaging, tightly closed.
Child Safety Keep out of the sight and reach of children, securing it in a safe location.

Disposal of Expired or Unused Product

Discard any expired or unneeded Melleva by following the official guidelines, ensuring the medicine is disposed of in a way that prevents access by children and others. Consult a pharmacist or doctor for guidance on local medicine take-back options.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Melleva found in:

A-Z Index: